Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 7 studies | 24% ± 6% | |
endothelial cell | 6 studies | 23% ± 6% | |
natural killer cell | 5 studies | 18% ± 1% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 21% ± 3% | |
microglial cell | 5 studies | 22% ± 5% | |
macrophage | 5 studies | 21% ± 3% | |
T cell | 4 studies | 21% ± 7% | |
plasmacytoid dendritic cell | 4 studies | 20% ± 6% | |
epithelial cell | 4 studies | 20% ± 3% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 20% ± 3% | |
lymphocyte | 4 studies | 24% ± 8% | |
astrocyte | 4 studies | 28% ± 6% | |
glutamatergic neuron | 4 studies | 44% ± 13% | |
oligodendrocyte precursor cell | 4 studies | 26% ± 8% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
GABAergic neuron | 3 studies | 44% ± 6% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 19% ± 2% | |
gamma-delta T cell | 3 studies | 23% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 2276.33 | 459 / 459 | 100% | 32.34 | 1118 / 1118 |
esophagus | 100% | 1698.37 | 1445 / 1445 | 100% | 32.71 | 183 / 183 |
uterus | 100% | 2570.77 | 170 / 170 | 100% | 31.38 | 459 / 459 |
lung | 100% | 2235.22 | 578 / 578 | 100% | 26.72 | 1154 / 1155 |
prostate | 100% | 1974.03 | 245 / 245 | 100% | 22.68 | 501 / 502 |
ovary | 100% | 2351.47 | 180 / 180 | 100% | 26.70 | 429 / 430 |
bladder | 100% | 2042.19 | 21 / 21 | 100% | 21.45 | 502 / 504 |
thymus | 100% | 2260.38 | 653 / 653 | 100% | 30.16 | 602 / 605 |
intestine | 100% | 2245.85 | 966 / 966 | 99% | 21.48 | 524 / 527 |
brain | 99% | 1310.82 | 2626 / 2642 | 100% | 25.35 | 705 / 705 |
stomach | 100% | 1570.00 | 359 / 359 | 99% | 22.93 | 284 / 286 |
pancreas | 100% | 1104.85 | 327 / 328 | 99% | 20.51 | 177 / 178 |
kidney | 100% | 1322.13 | 89 / 89 | 98% | 19.04 | 881 / 901 |
skin | 100% | 2117.53 | 1809 / 1809 | 97% | 21.34 | 457 / 472 |
adrenal gland | 100% | 1508.92 | 258 / 258 | 95% | 13.26 | 218 / 230 |
liver | 100% | 1294.29 | 226 / 226 | 92% | 11.16 | 373 / 406 |
adipose | 100% | 2158.65 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1830.23 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.05 | 29 / 29 |
muscle | 100% | 1413.37 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3818.37 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 41.60 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.04 | 1 / 1 |
heart | 98% | 1059.16 | 844 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 2388.95 | 904 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 11.03 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0016567 | Biological process | protein ubiquitination |
GO_0040029 | Biological process | epigenetic regulation of gene expression |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0072487 | Cellular component | MSL complex |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0005515 | Molecular function | protein binding |
GO_0140585 | Molecular function | promoter-enhancer loop anchoring activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0141054 | Molecular function | histone H2B ubiquitin ligase activity |
Gene name | MSL2 |
Protein name | E3 ubiquitin-protein ligase MSL2 (EC 2.3.2.-) (E3 ubiquitin-protein transferase MSL2) (Male-specific lethal 2-like 1) (MSL2-like 1) (Male-specific lethal-2 homolog) (MSL-2) (Male-specific lethal-2 homolog 1) (RING finger protein 184) MSL complex subunit 2 E3 ubiquitin-protein ligase MSL2 |
Synonyms | RNF184 MSL2L1 KIAA1585 |
Description | FUNCTION: Component of histone acetyltransferase complex responsible for the majority of histone H4 acetylation at lysine 16 which is implicated in the formation of higher-order chromatin structure. Acts as an E3 ubiquitin ligase that promotes monoubiquitination of histone H2B at 'Lys-35' (H2BK34Ub), but not that of H2A. This activity is greatly enhanced by heterodimerization with MSL1. H2B ubiquitination in turn stimulates histone H3 methylation at 'Lys-4' (H3K4me) and 'Lys-79' (H3K79me) and leads to gene activation, including that of HOXA9 and MEIS1. . |
Accessions | ENST00000473093.2 [Q9HCI7-2] ENST00000703105.1 ENST00000703104.1 [Q9HCI7-2] C9IZG7 ENST00000434835.2 [Q9HCI7-2] ENST00000703103.1 [Q9HCI7-2] ENST00000481989.2 [Q9HCI7-2] C9IZ03 ENST00000491050.2 [Q9HCI7-2] A0A8V8TR57 C9J5S2 ENST00000309993.3 [Q9HCI7-1] Q9HCI7 ENST00000491050.1 ENST00000481989.1 ENST00000473093.1 |